Chronic Kidney Disease Serum
Chronic Kidney Disease Serum from IRB-consented donors with clinically confirmed CKD, stratifiable by eGFR stage, aetiology, and dialysis status. Ideal for renal biomarker discovery, mineral metabolism and FGF23 research, uraemic solute profiling, and progression-risk modelling.
Human Chronic Kidney Disease Serum for Renal Biomarker and Metabolic Research
Our Chronic Kidney Disease Serum is sourced from IRB-consented donors clinically diagnosed with chronic kidney disease (CKD). Each sample is processed and frozen within 24 hours of collection to preserve filtration markers, mineral metabolism analytes, retained solutes, and inflammatory proteins for renal research.
Why Serum for Chronic Kidney Disease Research
CKD is a progressive loss of functioning nephrons with glomerulosclerosis and tubulointerstitial fibrosis, most commonly secondary to diabetes or hypertension. It is not an autoimmune disease in most donors. Because the kidney’s job is to regulate the composition of blood, serum is the direct readout of the failing organ — the disease is defined by what accumulates in it.
- Filtration markers define disease stage — serum creatinine and cystatin C are the basis of estimated GFR and therefore of CKD staging, making serum the matrix in which the disease is quantified
- Retained uraemic solutes accumulate — protein-bound gut-derived solutes and other retention products build up as clearance falls and are increasingly studied as mediators rather than passive markers
- Mineral and bone disorder axis — phosphate, calcium, parathyroid hormone, FGF23, and vitamin D metabolites shift in a characteristic sequence as CKD progresses, and are all measurable in serum
- Anaemia of CKD — reduced erythropoietin production together with disordered iron handling, including hepcidin, ferritin, and transferrin saturation, is a defining systemic consequence of nephron loss
- Low-grade inflammation drives cardiovascular risk — elevated CRP, IL-6, and soluble TNF receptors are consistently observed in CKD and link renal decline to the cardiovascular mortality that dominates outcomes
- Aetiology shapes the profile — diabetic and hypertensive nephropathy, glomerular disease, and polycystic kidney disease progress differently, so specifying the underlying cause materially changes the biology of the cohort
Donor Stratification Available
- CKD stage — eGFR category from G1 through G5 where recorded
- Albuminuria category — where measured and available
- Primary aetiology — diabetic kidney disease, hypertensive nephrosclerosis, glomerulonephritis, or polycystic kidney disease
- Dialysis and transplant status — non-dialysis CKD, haemodialysis, peritoneal dialysis, or post-transplant
- Comorbidity — diabetes, hypertension, cardiovascular disease, or anaemia where documented
- Treatment status — RAS blockade, SGLT2 inhibitor, mineralocorticoid receptor antagonist, phosphate binder, or erythropoiesis-stimulating agent
- Matched healthy controls available — demographically matched donors with normal renal function
Product Features
- Collected from clinically confirmed CKD donors
- Processed and frozen within 24 hours of collection
- Research Use Only (RUO)
- Standard and custom aliquot volumes available
- IRB-approved protocols with documented consent
De-identified Donor Data
- Diagnosis confirmation and CKD stage where recorded
- Age, sex assigned at birth, and ethnicity
- Donor-reported allergy, medication, and infectious disease history
- Renal function values, aetiology, and dialysis status available on request
Applications
- Creatinine, cystatin C, and eGFR assay development and validation
- Novel renal biomarker discovery and progression-risk modelling
- Mineral and bone disorder research including FGF23 and parathyroid hormone
- Uraemic solute and metabolomic profiling across CKD stages
- Anaemia of CKD and iron regulation studies including hepcidin
- Inflammation and cardiovascular risk marker profiling
- Proteomic profiling stratified by stage and aetiology
- Therapeutic candidate screening and treatment response research
Other Chronic Kidney Disease Specimen Types
Matched material from the same CKD donor pool is available as chronic kidney disease plasma, whole blood, PBMC, and leukopak. Related renal cohorts include diabetic nephropathy PBMC and diabetic kidney disease PBMCs.
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Chronic kidney disease serum is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse the full specimen range and healthy-donor controls, see our human serum collection.
Protocols & Documentation
-
Download
Serum Isolation
Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Serum
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Serum cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.